Telix Pharmaceuticals Ltd has released a press release.
CMS payment improvement decision for radiopharma diagnostics
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- FDA accepts NDA and grants priority review for Pixclara
- Telix Files Form 20-F Registration Statement for Nasdaq ADS
- Telix Q3 2024 Revenue and Business Update
- Telix to Acquire RLS for US Manufacturing and Distribution
- Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent
Later from Telix Pharmaceuticals
- Telix Adds FAP-Targeting Theranostic Candidates to Pipeline
- Presentation to Accompany FAP-Targeting Acquisition
- TLX to Acquire Next-Gen Therapeutics and Biologics Platform
- Presentation to Accompany Biologics Platform Acquisition
- Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals